Funded by NIAID.
Vaxxel, a French start-up developing mucosal vaccines against respiratory viral infections is proud to announce positive preclinical in vivo efficacy results for Metavac®-RSV, its intranasal live-attenuated bivalent vaccine candidate to fight hMPV (human MetaPneumoVirus) and RSV (Respiratory Syncytial Virus) infections. These two pneumoviruses are the source of acute respiratory infections in humans such as bronchiolitis or pneumonia in children below 5 years old and in older adults above 65 years old. There is no vaccine available today against HMPV to protect the 195 million persons at risk (including 46 million children) from these severe infections (US and EU, 2020).